MARKET

BPTH

BPTH

Bio-Path Hldgs Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.328
+0.128
+3.04%
Opening 13:13 07/07 EDT
OPEN
4.300
PREV CLOSE
4.200
HIGH
4.460
LOW
4.300
VOLUME
37.79K
TURNOVER
120.97K
52 WEEK HIGH
8.62
52 WEEK LOW
2.680
MARKET CAP
30.99M
P/E (TTM)
-2.7093
1D
5D
1M
3M
1Y
5Y
Bio-Path Holdings Files $110 Million Mixed Shelf
MT Newswires · 05/31 04:14
BRIEF-Bio Path Holdings Inc Files For Mixed Shelf Of Up To $110 Million
reuters.com · 05/27 20:40
10 Biggest Price Target Changes For Thursday
Telsey Advisory Group cut the price target for Bath & Body Works, Inc. (NYSE: BBWI) from $70 to $60. Bath & Body Works shares fell 6.9% to $40.00 in pre-market trading.
Benzinga · 05/19 12:26
--HC Wainwright Adjusts Price Target on Bio-Path Holdings to $9 From $12, Reiterates Buy Rating
MT Newswires · 05/19 05:21
Bio-Path Holdings: Q1 Earnings Insights
  Bio-Path Holdings (NASDAQ:BPTH) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/17 11:46
BRIEF-Bio-Path Holdings Reports First Quarter 2022 Financial Results
reuters.com · 05/17 11:19
Bio-Path Holdings Q1 EPS $(0.47) Misses $(0.45) Estimate
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.45) by 4.44 percent. This is a 9.3 percent decrease over losses of $(0.43) per share from
Benzinga · 05/17 11:09
Bio-Path GAAP EPS of -$0.47 misses by $0.01
Bio-Path press release (NASDAQ:BPTH): Q1 GAAP EPS of -$0.47 misses by $0.01. As of March 31, 2022, the Company had cash of $21.2 million, compared to $23.8 million as of
Seekingalpha · 05/17 11:04
More
No Data
Learn about the latest financial forecast of BPTH. Analyze the recent business situations of Bio-Path Hldgs Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BPTH stock price target is 11.00 with a high estimate of 13.00 and a low estimate of 9.00.
High13.00
Average11.00
Low9.00
Current 4.328
EPS
Actual
Estimate
-0.47-0.35-0.24-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 34
Institutional Holdings: 922.78K
% Owned: 12.89%
Shares Outstanding: 7.16M
TypeInstitutionsShares
Increased
0
0
New
4
11.55K
Decreased
5
20.19K
Sold Out
4
48.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.00%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Director of Investor Relations/Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Aline Sherwood
No Data
No Data
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.